Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 4:16 pm Purchase |
2024-12-31 | 13G | Upstream Bio, Inc. UPB |
HBM BIOVENTURES CAYMAN LTD | 2,715,056 5.100% |
2,715,056 (New Position) |
Filing History |
| 2025-02-13 4:15 pm Purchase |
2023-12-31 | 13G | IO Biotech, Inc. IOBT |
HBM BIOVENTURES CAYMAN LTD | 5,523,439 8.200% |
1,578,947 (+40.03%) |
Filing History |
| 2025-02-13 4:15 pm Unchanged |
2024-12-31 | 13G | Benitec Biopharma Inc. BNTC |
HBM BIOVENTURES CAYMAN LTD | 1,041,669 4.500% |
0 (Unchanged) |
Filing History |
| 2024-12-27 4:05 pm Purchase |
2024-12-18 | 13G | ALX Oncology Holdings Inc. ALXO |
HBM BIOVENTURES CAYMAN LTD | 3,426,929 6.500% |
3,426,929 (New Position) |
Filing History |
| 2024-11-13 4:19 pm Unchanged |
2024-09-30 | 13G | Mineralys Therapeutics, Inc. MLYS |
HBM BIOVENTURES CAYMAN LTD | 2,246,332 4.500% |
0 (Unchanged) |
Filing History |
| 2024-11-13 4:18 pm Purchase |
2024-09-30 | 13G | Benitec Biopharma Inc. BNTC |
HBM BIOVENTURES CAYMAN LTD | 1,041,669 9.700% |
191,776 (+22.56%) |
Filing History |
| 2024-04-29 4:05 pm Purchase |
2024-04-17 | 13G | Benitec Biopharma Inc. BNTC |
HBM BIOVENTURES CAYMAN LTD | 849,893 9.990% |
849,893 (New Position) |
Filing History |
| 2024-02-13 4:09 pm Purchase |
2023-12-31 | 13G | Mineralys Therapeutics, Inc. MLYS |
HBM BIOVENTURES CAYMAN LTD | 2,246,332 5.500% |
2,246,332 (New Position) |
Filing History |
| 2024-02-13 4:08 pm Sale |
2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
HBM BIOVENTURES CAYMAN LTD | 3,297,800 7.600% |
-516,053 (-13.53%) |
Filing History |
| 2024-02-13 4:07 pm Sale |
2024-02-06 | 13G | Longboard Pharmaceuticals, Inc. LBPH |
HBM BIOVENTURES CAYMAN LTD | 0 0.000% |
-1,345,009 (Position Closed) |
Filing History |
| 2024-02-13 4:06 pm Sale |
2023-12-31 | 13G | IO Biotech, Inc. IOBT |
HBM BIOVENTURES CAYMAN LTD | 3,944,492 6.000% |
-1,578,947 (-28.59%) |
Filing History |
| 2024-02-13 4:06 pm Purchase |
2023-12-31 | 13G | Alimera Sciences, Inc. ALIM |
HBM BIOVENTURES CAYMAN LTD | 466,666 0.900% |
466,666 (New Position) |
Filing History |
| 2023-08-15 3:15 pm Purchase |
2023-08-09 | 13G | IO Biotech, Inc. IOBT |
HBM BIOVENTURES CAYMAN LTD | 5,523,439 8.190% |
1,524,008 (+38.11%) |
Filing History |
| 2023-08-14 3:45 pm Purchase |
2023-08-09 | 13G | IO Biotech, Inc. IOBT |
HBM BIOVENTURES CAYMAN LTD | 3,999,431 6.100% |
1,578,947 (+65.23%) |
Filing History |
| 2023-02-14 4:03 pm Purchase |
2022-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
HBM BIOVENTURES CAYMAN LTD | 3,813,853 8.700% |
722,899 (+23.39%) |
Filing History |
| 2023-02-14 4:02 pm Sale |
2022-12-31 | 13G | Harmony Biosciences Holdings, Inc. HRMY |
HBM BIOVENTURES CAYMAN LTD | 2,147,943 3.600% |
-2,397,300 (-52.74%) |
Filing History |
| 2023-02-14 4:02 pm Sale |
2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
HBM BIOVENTURES CAYMAN LTD | 8,400,000 3.100% |
-8,456,567 (-50.17%) |
Filing History |
| 2023-02-14 4:01 pm Purchase |
2022-12-31 | 13G | Longboard Pharmaceuticals, Inc. LBPH |
HBM BIOVENTURES CAYMAN LTD | 1,345,009 9.990% |
17,579 (+1.32%) |
Filing History |
| 2022-02-11 4:04 pm Sale |
2021-12-31 | 13G | BioAtla, Inc. BCAB |
HBM BIOVENTURES CAYMAN LTD | 1,427,317 4.000% |
-1,263,552 (-46.96%) |
Filing History |
| 2022-02-11 4:03 pm Sale |
2021-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
HBM BIOVENTURES CAYMAN LTD | 16,856,567 6.900% |
-898,156 (-5.06%) |
Filing History |